Compatibility of a Novel @entity39244 Analog with Fertility and Pregnancy in a Xenograft XXXX Model of @entity46 .

@entity1 @entity249 @entity39244 @entity455 @entity50530 @entity3111 @entity13374 @entity19 @entity75 @entity46 @entity1017 @entity5231
UNASSIGNED: @entity46 is a @entity13374 defined by the growth of endometrium outside of the uterus. Although @entity46 contributes to 50% of female @entity249 cases, medical treatments are incompatible with pregnancy. Angiogenesis, the growth of blood vessels from existing vasculature, plays a crucial role in endometriotic lesion growth and survival. Previously, we demonstrated the effectiveness of @entity39244 analog, @entity50530 (Abbott Laboratories) to inhibit @entity455 in @entity19 . We have now evaluated the trans-generational implications of @entity50530 treatment before and during @entity19 pregnancy. We hypothesized that @entity50530 would @entity75 vasculature without affecting pregnancy, offspring development, or ovarian and uterine vascularity in @entity19 . @entity46 was induced using @entity1 endometrium in b-estradiol-primed BALB/c-Rag-2-/-Il2ry-/- @entity19 receiving intraperitoneal injections of @entity50530 (25 mg/kg) or 5% dextrose control for 21 days. Ultrasound assessment of lesion vascularization revealed a reduction in blood flow supplying treated lesions. Excised @entity50530 treated lesions stained for @entity5231 + endothelial cells exhibited a decrease in microvessel density. Following confirmation of estrous cycling, @entity19 were bred and treated with @entity50530 on gestation days 7, 9, 11, 13, 15, 17, and 19. @entity50530 did not affect estrous cycling or pregnancy parameters including litter size across generations and offspring @entity1017 . Quantification of angiogenic cytokine plasma levels revealed no significant differences between treatment groups. @entity3111 staining of the uterus and ovary revealed no observable effects of @entity50530 . Similarly, no obvious histological anomalies were observed in the kidney, liver, ovary, or uterus following @entity50530 treatment. These results suggest that @entity50530 effectively inhibit @entity455 without affecting trans-generational pregnancy outcomes in @entity19 .
